Aktuellt
SENASTE
Redeye endorses yesterday’s news that Idogen has enrolled the first patient in its phase l/lla-trial. This marks a concrete step forward for Idogen, which is now a clinical-stage entity. Each patient enrolled is important, as information will be gathered sequentially, revealing initial data points on the treatment’s safety and potential efficacy.
LÄS MER
